Tags

Type your tag names separated by a space and hit enter

Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II).
Am J Trop Med Hyg. 2007 Feb; 76(2):208-23.AJ

Abstract

The fixed dose combination of atovaquone and proguanil hydrochloride, marketed under the trade name Malarone, is the most recently approved agent in North America for the prevention and treatment of chloroquine- and multi-drug resistant Plasmodium falciparum malaria. In both adult and pediatric populations, atovaquone-proguanil demonstrates consistently high protective efficacy against P. falciparum, and in treatment trials, cure rates exceed 93%. Only a handful of genetically confirmed treatment failures have been reported to date. Atovaquone-proguanil has an excellent safety profile during both prophylaxis and treatment courses, with severe adverse events rarely reported. This topical review will examine the evidence behind the current indications for use of atovaquone-proguanil, and will summarize the current body of literature surrounding safety and tolerability.

Authors+Show Affiliations

Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada. andrea.boggild@utoronto.caNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Congress

Language

eng

PubMed ID

17297027

Citation

Boggild, Andrea K., et al. "Atovaquone-proguanil: Report From the CDC Expert Meeting On Malaria Chemoprophylaxis (II)." The American Journal of Tropical Medicine and Hygiene, vol. 76, no. 2, 2007, pp. 208-23.
Boggild AK, Parise ME, Lewis LS, et al. Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). Am J Trop Med Hyg. 2007;76(2):208-23.
Boggild, A. K., Parise, M. E., Lewis, L. S., & Kain, K. C. (2007). Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). The American Journal of Tropical Medicine and Hygiene, 76(2), 208-23.
Boggild AK, et al. Atovaquone-proguanil: Report From the CDC Expert Meeting On Malaria Chemoprophylaxis (II). Am J Trop Med Hyg. 2007;76(2):208-23. PubMed PMID: 17297027.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Atovaquone-proguanil: report from the CDC expert meeting on malaria chemoprophylaxis (II). AU - Boggild,Andrea K, AU - Parise,Monica E, AU - Lewis,Linda S, AU - Kain,Kevin C, PY - 2007/2/14/pubmed PY - 2007/4/4/medline PY - 2007/2/14/entrez SP - 208 EP - 23 JF - The American journal of tropical medicine and hygiene JO - Am. J. Trop. Med. Hyg. VL - 76 IS - 2 N2 - The fixed dose combination of atovaquone and proguanil hydrochloride, marketed under the trade name Malarone, is the most recently approved agent in North America for the prevention and treatment of chloroquine- and multi-drug resistant Plasmodium falciparum malaria. In both adult and pediatric populations, atovaquone-proguanil demonstrates consistently high protective efficacy against P. falciparum, and in treatment trials, cure rates exceed 93%. Only a handful of genetically confirmed treatment failures have been reported to date. Atovaquone-proguanil has an excellent safety profile during both prophylaxis and treatment courses, with severe adverse events rarely reported. This topical review will examine the evidence behind the current indications for use of atovaquone-proguanil, and will summarize the current body of literature surrounding safety and tolerability. SN - 0002-9637 UR - https://www.unboundmedicine.com/medline/citation/17297027/full_citation L2 - http://www.ajtmh.org/cgi/pmidlookup?view=long&pmid=17297027 DB - PRIME DP - Unbound Medicine ER -